

Cover Story
Guest Editorial
As the world faced the threat of a novel respiratory pathogen, SARS-CoV-2, in the first months of 2020, there was a great deal of uncertainty about its effect on people, especially those living with a diagnosis of cancer.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Abdallah Abou Zahr, an oncologist whose cancer story resonated widely, dies of liposarcoma at 42
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Antibody halts triple-negative breast cancer in preclinical models
- Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill
- Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- FDA delays drug reviews in new voucher program amid safety, efficacy concerns














